Page last updated: 2024-12-06

sizofiran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sizofiran: A beta-D-glucan obtained from the Aphyllophoral fungus Schizophyllum commune. It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24777
SCHEMBL ID1517238
MeSH IDM0019497

Synonyms (7)

Synonym
sizofiran
sonifilan
(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol
SCHEMBL1517238
DTXSID00238184 ,
NCGC00532495-01
YS46139

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with sizofiran and 5-fluorouracil in combination improved (P = 0.003) the 5-year survival in 60 patients treated with radiotherapy."( Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival.
Fujisaki, S; Fukuma, K; Katabuchi, H; Miyazaki, K; Mizutani, H; Okamura, H, 1995
)
0.84

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the clinical effect of a biological response modifier (BRM), sizofiran (SPG), combined with irradiation, a randomized controlled study was performed in patients with stage II or III cervical cancer involving the collaboration of 52 institutes throughout Japan."( Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer.
Akiya, K; Hashimoto, S; Kasamatsu, T; Noda, K; Ozawa, M; Sekiba, K; Sugimori, H; Takeuchi, S; Tomoda, Y; Yajima, A, 1992
)
0.84
" The present results indicate that SPG-immunotherapy combined with radiotherapy not only induces the cytotoxic activity of macrophage but also augments NK activity in the patients with uterine cervical cancer."( [Electron microscopic and immunological studies concerning the effect on the antitumor activity of sizofiran (SPG) combined with radiotherapy for cervical cancer].
Hasegawa, K; Kimura, A; Kinugasa, M; Mizuhira, V; Nishimura, R; Ohtsu, F; Okamura, M; Takeuchi, K, 1990
)
0.5
"To investigate the immunological effect of Sizofilan (SPG) combined with radiotherapy, we evaluated the immunological parameters in 22 patients with uterine cervical cancers."( [The study on the immunological effect of sizofilan combined with radiotherapy in patients with uterine cervical cancer].
Aida, I; Izumi, A; Sekiguchi, I; Suzuki, M; Tamada, T, 1990
)
0.28
" Immunization with antigenic peptides, OVA257-264, did not induce these antigen-specific immune responses even in combination with CpG-dA/SPG, indicating that peptides require a carrier to antigen presenting cells."( Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Aoshi, T; Ishii, KJ; Kobiyama, K; Mochizuki, S; Morishita, H; Sakurai, K, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" The present study demonstrated that the activation of peritoneal M phi could be maintained and its number was increased by repeated dosing of sizofiran and rIFN-gamma in combination every three or four days in patients with ovarian cancer."( Maintenance of the activation of peritoneal macrophages in patients with ovarian cancer by sizofiran and recombinant interferon-gamma.
Chen, JT; Hasumi, K; Masubuchi, K, 1992
)
0.71
" However, a higher optimal dosage of schizophyllan was obtained in the experiments."( Flocculation of hematite particles by a comparatively large rigid polysaccharide: schizophyllan.
Buffle, J; Ferretti, R; Stoll, S; Zhang, J, 2003
)
0.32
" According to the results, SPG at 10 µg/ml concentration was determined as the optimal dosage for differentiation studies."( Schizophyllan promotes osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells in vitro.
Ghiasi, M; Halabian, R; Hatamian-Zarmi, A; Hemati, S; Salimi, A, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (248)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (19.35)18.7374
1990's79 (31.85)18.2507
2000's66 (26.61)29.6817
2010's33 (13.31)24.3611
2020's22 (8.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.28 (24.57)
Research Supply Index5.64 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (6.84%)5.53%
Reviews8 (3.04%)6.00%
Case Studies7 (2.66%)4.05%
Observational0 (0.00%)0.25%
Other230 (87.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer [NCT01926821]Phase 1200 participants (Anticipated)Interventional2013-05-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]